Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence ; volume:22 ; number:1 ; day:27 ; month:5 ; year:2023 ; pages:1-12 ; date:12.2023
Cardiovascular diabetology ; 22, Heft 1 (27.5.2023), 1-12, 12.2023
- Urheber
-
Schechter, Meir
Melzer Cohen, Cheli
Fishkin, Alisa
Rozenberg, Aliza
Yanuv, Ilan
Sehtman-Shachar, Dvora R.
Chodick, Gabriel
Clark, Alice
Abrahamsen, Trine J.
Lawson, Jack
Karasik, Avraham
Mosenzon, Ofri
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12933-023-01829-0
- URN
-
urn:nbn:de:101:1-2023091109030518404619
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schechter, Meir
- Melzer Cohen, Cheli
- Fishkin, Alisa
- Rozenberg, Aliza
- Yanuv, Ilan
- Sehtman-Shachar, Dvora R.
- Chodick, Gabriel
- Clark, Alice
- Abrahamsen, Trine J.
- Lawson, Jack
- Karasik, Avraham
- Mosenzon, Ofri
- SpringerLink (Online service)
Ähnliche Objekte (12)
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency
Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin
Safety and Efficacy of GLP-1 Agonists in a Cohort of Patients with Fontan Circulation
GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Albuminuria
Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency
Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin
Safety and Efficacy of GLP-1 Agonists in a Cohort of Patients with Fontan Circulation
GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Albuminuria
Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency
Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin
Safety and Efficacy of GLP-1 Agonists in a Cohort of Patients with Fontan Circulation
GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Albuminuria